Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target

Chronic myeloid leukemia (CML) therapy has markedly improved patient prognosis after introduction of imatinib mesylate for clinical use. However, a subset of patients develops resistance to imatinib and other tyrosine kinase inhibitors (TKIs), mainly due to point mutations in the region encoding the...

Descripción completa

Detalles Bibliográficos
Autores principales: Toman, O., Kabickova, T., Vit, O., Fiser, R., Polakova, K. Machova, Zach, J., Linhartova, J., Vyoral, D., Petrak, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968618/
https://www.ncbi.nlm.nih.gov/pubmed/27430982
http://dx.doi.org/10.3892/or.2016.4945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968618/
https://www.ncbi.nlm.nih.gov/pubmed/27430982
http://dx.doi.org/10.3892/or.2016.4945

Ejemplares similares